Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia; Coronary Heart Disease; Peripheral Vascular Disease; Cerebrovascular Accident; Diabetes
Intervention: Rosuvastatin (Drug)
Phase: N/A
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Ingrid van Geel, Study Chair, Affiliation: CV
Ingeborg Vosjan, Study Chair, Affiliation: CV
Summary
In an observational multi-centre study (HEROS), the effects of starting treatment with
rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement,
in patients with a dissimilar high-risk profile who had not been treated with cholesterol
lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment
and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were
studied.
Clinical Details
Official title: Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Study design: Cohort, Prospective
Primary outcome: Effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who hadn't been treated with cholesterol lowering drugs in the past 3 months.
Secondary outcome: Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients who had not been treated with cholesterol lowering drugs at least in the past
three months, with an LDL-C 3. 2 mmol/l.
- According to the advise of the CBO, and could be included in one of the following risk
groups: secondary prevention, DM or primary prevention.
- The general practice investigator made the decision to start treatment with
rosuvastatin irrespective of study participation.
- Patient approved to place anonymous results at the disposal of AstraZeneca
Exclusion Criteria:
- Patients with symptoms of myalgia, myopathy or liver function insufficiency (including
raised serum transaminases) which bear a causal relation to the treatment with
statins, patients with familiar dyslipidemia and/or patients with contra-indications
for treatment with rosuvastatin
Locations and Contacts
Additional Information
Starting date: May 2003
Ending date: February 2006
Last updated: April 24, 2008
|
